Interleukin-17 antagonists in the treatment of psoriasis

Journal of Cutaneous Medicine and Surgery
Shivani Felicia Chandrakumar, Jensen Yeung

Abstract

Psoriasis is a chronic, immune-mediated inflammatory skin disorder of unknown etiology. Interleukin (IL)-17a, a key product of the recently identified Th17 cell subset, has been found to play a critical role in the immunopathogenesis of psoriasis. IL-17 antagonists are a new class of biological agent currently in development for psoriasis that selectively inhibit IL-17a activity. This review aims to summarize the current efficacy data from phase II randomized controlled trials of the IL-17 antagonists brodalumab, ixekizumab, and secukinumab for the treatment of moderate to severe psoriasis. Patients treated with IL-17 antagonists achieved marked reduction in psoriasis disease severity as demonstrated by the Psoriasis Area and Severity Index (PASI) 75 response rates. A sizable proportion of patients treated with brodalumab and ixekizumab achieved unprecedented clinical clearance of their psoriasis (PASI > 90). These encouraging results demonstrate the efficacy of these agents and validate the pro-inflammatory role of IL-17 in the pathophysiology of psoriasis.

References

Jun 14, 2005·The British Journal of Dermatology·K A PappUNKNOWN Etanercept Psoriasis Study Group
Oct 4, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Rolf E KuestnerSteven D Levin
Oct 16, 2007·Journal of the American Academy of Dermatology·Alan MenterKim Papp
Nov 28, 2007·The Journal of Experimental Medicine·Lisa C ZabaJames G Krueger
Jul 11, 2008·The Journal of Investigative Dermatology·Kilian EyerichClaudia Traidl-Hoffmann
Nov 10, 2009·The Journal of Allergy and Clinical Immunology·Lisa C ZabaJames G Krueger
May 25, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrew M LinAllen T Bruce
Mar 20, 2012·Clinical Reviews in Allergy & Immunology·Anupam MitraHermenio Cavalcante Lima
Mar 30, 2012·The New England Journal of Medicine·Kim A PappScott Baumgartner
Mar 30, 2012·The New England Journal of Medicine·Craig LeonardiSubhashis Banerjee
Jun 9, 2012·Nature Biotechnology·Ken Garber
Aug 14, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P Berche
Sep 28, 2012·The Journal of Investigative Dermatology·Rosa ParisiUNKNOWN Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team
Dec 21, 2012·International Journal of Rheumatic Diseases·In Seol YooSeong Wook Kang
Jun 5, 2013·Expert Opinion on Investigational Drugs·Andrea Chiricozzi, James G Krueger
Sep 28, 2013·Expert Opinion on Therapeutic Targets·Tej Pratap SinghJoshua M Farber
Oct 26, 2013·Seminars in Arthritis and Rheumatism·Wim B van den Berg, Iain B McInnes

❮ Previous
Next ❯

Citations

Jan 26, 2016·Autoimmunity Reviews·Rasnik K SinghWilson Liao
Sep 7, 2018·The Annals of Pharmacotherapy·Sydney K SheltonAmy Heck Sheehan
Oct 21, 2016·Expert Opinion on Investigational Drugs·Molly Campa, Alan Menter
Dec 1, 2018·Expert Opinion on Biological Therapy·Annika Silfvast-KaiserAlan Menter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Related Papers

Clinical, Cosmetic and Investigational Dermatology
Ann Sophie LønnbergLone Skov
The Journal of Dermatological Treatment
Gabrielle BrownEthan Levin
Expert Review of Clinical Immunology
Beatrice Dyring-AndersenClaus Zachariae
© 2021 Meta ULC. All rights reserved